Aclaris Therapeutics Inc. (ACRS)
NASDAQ: ACRS
· Real-Time Price · USD
1.45
0.07 (5.07%)
At close: May 02, 2025, 3:59 PM
1.44
-0.69%
After-hours: May 02, 2025, 04:18 PM EDT
5.07% (1D)
| Bid | 1.3 |
| Market Cap | 157.01M |
| Revenue (ttm) | 18.72M |
| Net Income (ttm) | -132.06M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.85 |
| Forward PE | -1.88 |
| Analyst | Buy |
| Ask | 1.5 |
| Volume | 575,586 |
| Avg. Volume (20D) | 878,474 |
| Open | 1.40 |
| Previous Close | 1.38 |
| Day's Range | 1.37 - 1.46 |
| 52-Week Range | 0.95 - 5.17 |
| Beta | 0.54 |
About ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 6, 2015
Employees 61
Stock Exchange NASDAQ
Ticker Symbol ACRS
Website https://www.aclaristx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 624.14% from the latest price.
Stock ForecastsNext Earnings Release
Aclaris Therapeutics Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-2.65%
Aclaris shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
+46.18%
Aclaris Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $3 to $13. Also, BTIG upgraded the stock from Neutral to Buy and announced a price target of $8.
